Handbook of therapeutic antibodies: 2 [Emerging developments]
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | English |
| Veröffentlicht: |
Weinheim
Wiley-VCH
2007
|
| Online-Zugang: | Inhaltsverzeichnis |
| Beschreibung: | XXIX S., S. 325 - 693 Ill., graph. Darst. |
Internformat
MARC
| LEADER | 00000nam a2200000 cc4500 | ||
|---|---|---|---|
| 001 | BV022285710 | ||
| 003 | DE-604 | ||
| 005 | 00000000000000.0 | ||
| 007 | t | ||
| 008 | 070226s2007 ad|| |||| 00||| eng d | ||
| 035 | |a (OCoLC)315778616 | ||
| 035 | |a (DE-599)BVBBV022285710 | ||
| 040 | |a DE-604 |b ger |e rakwb | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-19 |a DE-29 |a DE-355 |a DE-703 |a DE-188 |a DE-578 | ||
| 084 | |a QW 575 |2 nlm | ||
| 245 | 1 | 0 | |a Handbook of therapeutic antibodies |n 2 |p [Emerging developments] |c ed. by Stefan Dübel |
| 264 | 1 | |a Weinheim |b Wiley-VCH |c 2007 | |
| 300 | |a XXIX S., S. 325 - 693 |b Ill., graph. Darst. | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b n |2 rdamedia | ||
| 338 | |b nc |2 rdacarrier | ||
| 700 | 1 | |a Dübel, Stefan |e Sonstige |0 (DE-588)111685311 |4 oth | |
| 773 | 0 | 8 | |w (DE-604)BV022285689 |g 2 |
| 856 | 4 | 2 | |m HBZ Datenaustausch |q application/pdf |u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015495936&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |3 Inhaltsverzeichnis |
| 999 | |a oai:aleph.bib-bvb.de:BVB01-015495936 | ||
Datensatz im Suchindex
| _version_ | 1804136296424144896 |
|---|---|
| adam_text | Contents
Volume II
Overview of Therapeutic Antibodies XV
A Greeting by the Editor XVII
Foreword XIX
List of Authors XXI
Part III Beyond IgC Modified Antibodies
1 Immunoscintigraphy and Radioimmunotherapy 325
Jason L. J. Dearling and Alexandra Huhalov
1.1 Introduction 325
1.2 Solid Tumors as Targets for Antibody Based Therapeutics 326
1.3 Antigen 326
1.4 Antibodies as Vehicles for Radionuclide Delivery 327
1.5 Radioisotope 334
1.6 Improving Radioimmunoscintigraphy and Therapy 337
1.7 Summary 338
References 339
2 Bispecific Antibodies 345
Dafne Muller and Roland E. Kontermann
2.1 Introduction 345
2.2 The Generation of Bispecific Antibodies 346
2.3 Bispecific Antibodies and Retargeting of Effector Cells 354
2.4 Bispecific Antibodies and Retargeting of Effector Molecules 361
2.5 Bispecific Antibodies as Agonists or Antagonists 364
2.6 Bispecific Antibodies and Somatic Gene Therapy 366
2.7 Outlook 367
References 368
Handbook of Therapeutic Antibodies. Edited by Stefan Dlibel
Copyright © 2007 WILEY VCH Verlag GmbH Co. KGaA, Weinheim
ISBN 978 3 527 31453 9
VIM I Contents
3 Immunotoxins and Beyond: Targeted RNases 379
Susanna M. Rybak and Dianne L. Newton
3.1 Introduction 379
3.2 Immunotoxins 382
3.3 Targeted RNases 389
3.4 Targeted Onconase 394
3.5 Outlook 399
References 400
Part IV Emerging Concepts
4 Automation of Selection and Engineering 413
Zoltdn Konthur
4.1 Introduction 413
4.2 General Considerations for the Automation of Antibody
Generation 415
4.3 Development of an Antibody Generation Pipeline 417
4.4 Conclusion 427
References 428
5 Emerging Technologies for Antibody Selection 431
Mingyue He and Michael J. Taussig
5.1 Introduction 431
5.2 Display Technologies 432
5.3 Antibody Libraries 433
5.4 Antibody Selection and Maturation In Vitro 435
5.5 Linking Antibodies to mRNA: Ribosome and mRNA Display 436
5.6 Advantages of Ribosome Display 436
5.7 Ribosome Display Systems 437
5.8 Antibody Generation by Ribosome Display 440
5.9 Summary 440
References 441
6 Emerging Alternative Production Systems 445
Thomas Jostock
6.1 Introduction 445
6.2 Production Systems 446
6.3 Outlook 458
References 460
7 Non Antibody Scaffolds 467
Markus Fiedler and Arne Skerra
7.1 Introduction 467
7.2 Motivation for Therapeutic Use of Alternative Binding
Proteins 467
Contents IX
7.3 Single Domain Immunoglobulins 473
7.4 Scaffold Proteins Presenting a Contiguous Hypervariable Loop
Region 480
7.5 Scaffold Proteins for Display of Individual Extended
Loops 484
7.6 Scaffold Proteins Providing a Rigid Secondary Structure
Interface 488
7.7 Conclusions and Outlook: Therapeutic Potential and Ongoing
Developments 491
References 492
8 Emerging Therapeutic Concepts I: ADEPT 501
Surinder K. Sharma, Kerry A. Chester, and Kenneth D. Bagshawe
8.1 Introduction and Basic Principles of ADEPT 502
8.2 Preclinical Studies 503
8.3 Clinical Studies 505
8.4 Immunogenicity 506
8.5 Important Considerations/Outlook 508
References 509
9 Emerging Therapeutic Concepts II: Nanotechnology 515
Dimiter S. Dimitrov, Igor A. Sidorov, Yang Feng, Ponraj Prabakaran,
Michaela A.E. Arndt, Jurgen Krauss, and Susanna M. Rybak
9.1 Introduction 515
9.2 Nanoliposomes, Gold Nanoshells, Quantum Dots, and Other
Nanoparticles with Biomedical Potential 516
9.3 Conjugation of Antibodies to Nanoparticles 518
9.4 Nanoparticle Antibody Conjugates for the Treatment of Cancer and
Other Diseases 520
9.5 Comparison Between Nanoparticle Antibody Conjugates and Fusion
Proteins for Cancer Diagnosis and Treatment 522
9.6 Conclusions 526
9.7 Summary 526
References 527
Appendix 529
10 Emerging Therapeutic Concepts III: Chimeric Immunoglobulin
T Cell Receptors, T Bodies 533
Thomas Schirrmann and Cabriele Pecher
10.1 Introduction 533
10.2 Chimeric Immunoglobulin T Cell Receptors
T Bodies 534
10.3 Preclinical Studies 543
10.4 Therapeutic Considerations 552
X Contents
10.5 Perspectives 558
10.6 Conclusions 561
References 562
11 Emerging Therapeutic Concepts IV: Anti idiotypic Antibodies 573
Peter Fischer and Martina M. Uttenreuther Fischer
11.1 Introduction 573
11.2 Definition of Anti idiotypic Antibodies 573
11.3 Anti idiotypic Antibodies as Autoantigens 575
11.4 Anti idiotypes as a Tool for Generating Specific Antibodies 575
11.5 Intravenous Immunoglobulin Preparations (IVIG) 575
11.6 Anti idiotypic Antibodies as Possible Superantigens? 577
11.7 Anti idiotypic Antibodies in Cancer Therapy 578
11.8 Ab2|3 Vaccine Trials Mimicking GD2 580
11.9 Molecular Characterization of the Anti idiotypic Immune Response of a
Relapse free Cancer Patient 581
11.10 Conclusion 583
References 583
Part V Ongoing Clinical Studies
12 Antibodies in Phase l/ll/lll: Cancer Therapy 593
P. Markus Deckert
12.1 Introduction 593
12.2 Novel Antibody Constructs 595
12.3 Specific Targeting and Effector Mechanisms 606
12.4 Antigens Without Known Effector Function 627
12.5 Disease specific Concepts of Unknown Antigen Function and
Structure 656
12.6 Summary 656
References 659
13 Antibodies in Phase l/ll/lll: Targeting TNF 673
Martin H. Holtmann and Markus F. Neurath
13.1 Introduction 673
13.2 Inflammatory Bowel Disease 674
13.3 Pathophysiologic Role of T Cells 675
13.4 Tumor Necrosis Factor oc 675
13.5 TNF Receptors and Signaling 676
13.6 Anti TNF Antibodies and Fusion Proteins in Clinical Testing 679
13.7 Mechanisms of Action 683
13.8 Other Anti TNF Biologicals 683
13.9 Other Cytokine based and Anti CD4+ T Cell Approaches 684
13.10 Perspective 685
References 686
Contents I XI
Volume I
Overview of Therapeutic Antibodies XIX
A Greeting by the Editor XXI
Foreword XXIII
List of Authors XXV
Introduction
1 Therapeutic Antibodies From Past to Future 3
Stefan Diibel
Part I Selecting and Shaping the Antibody Molecule
2 Selection Strategies I: Monoclonal Antibodies 19
Gerhard Moldenhauer
3 Selection Strategies II: Antibody Phage Display 45
Michael Hust, Lars Toleikis and Stefan Dubel
4 Selection Strategies III: Transgenic Mice 69
Marianne Briiggemann, Jennifer A. Smith, Michael J. Osborn,
and Xiangang Zou
5 Bioinformatics Tools for Antibody Engineering 95
Andrew C.R. Martin and James Allen
6 Molecular Engineering I: Humanization 119
Jose W. Saldanha
7 Molecular Engineering II: Antibody Affinity 145
Lorin Roskos, Scott Klakamp, Meina Liang, Rosalin Arends,
and Larry Green
8 Molecular Engineering III: Fc Engineering 171
Matthias Peipp, Thomas Beyer, Michael Dechant, and Thomas Valerius
Part II The Way into the Clinic 197
9 Production and Downstream Processing 199
Klaus Bergemann, Christian Eckermann, Patrick Garidel,
Stefanos Grammatikos, AlexanderJacobi, Hitto Kaufmann,
Ralph Kempken, and Sandra Pisch Heberle
XII I Contents
10 Pharmaceutical Formulation and Clinical Application 239
Cabriele Reich
11 Immunogenicity of Antibody Therapeutics 267
Huub Schellekens, Daan Crommelin, and Wim Jiskoot
12 Regulatory Considerations 277
Marjorie A. Shapiro, Patrick C. Swann, and Melanie Hartsough
13 Intellectual Property Issues 301
Michael Braunagel and Rathin C. Das
Volume III
Overview of Therapeutic Antibodies XXIII
A Greeting by the Editor XXV
Foreword XXVII
List of Authors XXIX
Volume III Approved Therapeutics
1 Adalimumab (Humira) 697
Hartmut Kupper, Jochen Salfeld, Daniel Tracey, and Joachim R. Kalden
2 Alemtuzumab (MabCampath) 733
Thomas Elter, Andreas Engert, and Michael Hallek
3 Bevacizumab (Avastin) 779
Eduardo Diaz Rubio, Edith A. Perez, and Cuiseppe Ciaccone
4 Cetuximab (Erbitux, C 225) 813
Norbert Schleucher and Udo Vanhoefer
5 Efalizumab (Raptiva) 827
Karlheinz Schmitt Rau and Sigbertjahn
6 Tc Fanolesomab (NeutroSpec) 851
ChristopherJ. Palestro, Josephine N. Rini, and Charito Love
7 Gemtuzumab Ozogamicin (Mylotarg) 869
Matthias Peipp and Martin Cramatzki
Contents I XIII
8 Infliximab (Remicade) 885
Maria Wiekowski and Christian Antoni
9 Muromonab CD3 (Orthoclone OKT3) 905
Harald Becker
10 Natalizumab (Tysabri) 941
Sebastian Schimrigk and RalfCold
11 Omalizumab (Xolair)
Anti lmmunoglobulin E Treatment in Allergic Diseases 951
Claus Kroegel and Martin Foerster
12 Palivizumab (Synagis) 999
Alexander C. Schmidt
13 Rituximab (Rituxan) 1033
Michael Wenger
14 Trastuzumab (Herceptin)
A Treatment for HER2 Positive Breast Cancer 1109
Paul Ellis
15 Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab,
Edrecolomab, Ibritumomab, Igovomab, Nofetumomab, Satumomab,
Sulesomab, Tositumomab, and Votumumab 1131
Christian Menzel and Stefan Dijbel
Index 1149
|
| adam_txt |
Contents
Volume II
Overview of Therapeutic Antibodies XV
A Greeting by the Editor XVII
Foreword XIX
List of Authors XXI
Part III Beyond IgC Modified Antibodies
1 Immunoscintigraphy and Radioimmunotherapy 325
Jason L. J. Dearling and Alexandra Huhalov
1.1 Introduction 325
1.2 Solid Tumors as Targets for Antibody Based Therapeutics 326
1.3 Antigen 326
1.4 Antibodies as Vehicles for Radionuclide Delivery 327
1.5 Radioisotope 334
1.6 Improving Radioimmunoscintigraphy and Therapy 337
1.7 Summary 338
References 339
2 Bispecific Antibodies 345
Dafne Muller and Roland E. Kontermann
2.1 Introduction 345
2.2 The Generation of Bispecific Antibodies 346
2.3 Bispecific Antibodies and Retargeting of Effector Cells 354
2.4 Bispecific Antibodies and Retargeting of Effector Molecules 361
2.5 Bispecific Antibodies as Agonists or Antagonists 364
2.6 Bispecific Antibodies and Somatic Gene Therapy 366
2.7 Outlook 367
References 368
Handbook of Therapeutic Antibodies. Edited by Stefan Dlibel
Copyright © 2007 WILEY VCH Verlag GmbH Co. KGaA, Weinheim
ISBN 978 3 527 31453 9
VIM I Contents
3 Immunotoxins and Beyond: Targeted RNases 379
Susanna M. Rybak and Dianne L. Newton
3.1 Introduction 379
3.2 Immunotoxins 382
3.3 Targeted RNases 389
3.4 Targeted Onconase 394
3.5 Outlook 399
References 400
Part IV Emerging Concepts
4 Automation of Selection and Engineering 413
Zoltdn Konthur
4.1 Introduction 413
4.2 General Considerations for the Automation of Antibody
Generation 415
4.3 Development of an Antibody Generation Pipeline 417
4.4 Conclusion 427
References 428
5 Emerging Technologies for Antibody Selection 431
Mingyue He and Michael J. Taussig
5.1 Introduction 431
5.2 Display Technologies 432
5.3 Antibody Libraries 433
5.4 Antibody Selection and Maturation In Vitro 435
5.5 Linking Antibodies to mRNA: Ribosome and mRNA Display 436
5.6 Advantages of Ribosome Display 436
5.7 Ribosome Display Systems 437
5.8 Antibody Generation by Ribosome Display 440
5.9 Summary 440
References 441
6 Emerging Alternative Production Systems 445
Thomas Jostock
6.1 Introduction 445
6.2 Production Systems 446
6.3 Outlook 458
References 460
7 Non Antibody Scaffolds 467
Markus Fiedler and Arne Skerra
7.1 Introduction 467
7.2 Motivation for Therapeutic Use of Alternative Binding
Proteins 467
Contents IX
7.3 Single Domain Immunoglobulins 473
7.4 Scaffold Proteins Presenting a Contiguous Hypervariable Loop
Region 480
7.5 Scaffold Proteins for Display of Individual Extended
Loops 484
7.6 Scaffold Proteins Providing a Rigid Secondary Structure
Interface 488
7.7 Conclusions and Outlook: Therapeutic Potential and Ongoing
Developments 491
References 492
8 Emerging Therapeutic Concepts I: ADEPT 501
Surinder K. Sharma, Kerry A. Chester, and Kenneth D. Bagshawe
8.1 Introduction and Basic Principles of ADEPT 502
8.2 Preclinical Studies 503
8.3 Clinical Studies 505
8.4 Immunogenicity 506
8.5 Important Considerations/Outlook 508
References 509
9 Emerging Therapeutic Concepts II: Nanotechnology 515
Dimiter S. Dimitrov, Igor A. Sidorov, Yang Feng, Ponraj Prabakaran,
Michaela A.E. Arndt, Jurgen Krauss, and Susanna M. Rybak
9.1 Introduction 515
9.2 Nanoliposomes, Gold Nanoshells, Quantum Dots, and Other
Nanoparticles with Biomedical Potential 516
9.3 Conjugation of Antibodies to Nanoparticles 518
9.4 Nanoparticle Antibody Conjugates for the Treatment of Cancer and
Other Diseases 520
9.5 Comparison Between Nanoparticle Antibody Conjugates and Fusion
Proteins for Cancer Diagnosis and Treatment 522
9.6 Conclusions 526
9.7 Summary 526
References 527
Appendix 529
10 Emerging Therapeutic Concepts III: Chimeric Immunoglobulin
T Cell Receptors, T Bodies 533
Thomas Schirrmann and Cabriele Pecher
10.1 Introduction 533
10.2 Chimeric Immunoglobulin T Cell Receptors
"T Bodies" 534
10.3 Preclinical Studies 543
10.4 Therapeutic Considerations 552
X Contents
10.5 Perspectives 558
10.6 Conclusions 561
References 562
11 Emerging Therapeutic Concepts IV: Anti idiotypic Antibodies 573
Peter Fischer and Martina M. Uttenreuther Fischer
11.1 Introduction 573
11.2 Definition of Anti idiotypic Antibodies 573
11.3 Anti idiotypic Antibodies as Autoantigens 575
11.4 Anti idiotypes as a Tool for Generating Specific Antibodies 575
11.5 Intravenous Immunoglobulin Preparations (IVIG) 575
11.6 Anti idiotypic Antibodies as Possible Superantigens? 577
11.7 Anti idiotypic Antibodies in Cancer Therapy 578
11.8 Ab2|3 Vaccine Trials Mimicking GD2 580
11.9 Molecular Characterization of the Anti idiotypic Immune Response of a
Relapse free Cancer Patient 581
11.10 Conclusion 583
References 583
Part V Ongoing Clinical Studies
12 Antibodies in Phase l/ll/lll: Cancer Therapy 593
P. Markus Deckert
12.1 Introduction 593
12.2 Novel Antibody Constructs 595
12.3 Specific Targeting and Effector Mechanisms 606
12.4 Antigens Without Known Effector Function 627
12.5 Disease specific Concepts of Unknown Antigen Function and
Structure 656
12.6 Summary 656
References 659
13 Antibodies in Phase l/ll/lll: Targeting TNF 673
Martin H. Holtmann and Markus F. Neurath
13.1 Introduction 673
13.2 Inflammatory Bowel Disease 674
13.3 Pathophysiologic Role of T Cells 675
13.4 Tumor Necrosis Factor oc 675
13.5 TNF Receptors and Signaling 676
13.6 Anti TNF Antibodies and Fusion Proteins in Clinical Testing 679
13.7 Mechanisms of Action 683
13.8 Other Anti TNF Biologicals 683
13.9 Other Cytokine based and Anti CD4+ T Cell Approaches 684
13.10 Perspective 685
References 686
Contents I XI
Volume I
Overview of Therapeutic Antibodies XIX
A Greeting by the Editor XXI
Foreword XXIII
List of Authors XXV
Introduction
1 Therapeutic Antibodies From Past to Future 3
Stefan Diibel
Part I Selecting and Shaping the Antibody Molecule
2 Selection Strategies I: Monoclonal Antibodies 19
Gerhard Moldenhauer
3 Selection Strategies II: Antibody Phage Display 45
Michael Hust, Lars Toleikis and Stefan Dubel
4 Selection Strategies III: Transgenic Mice 69
Marianne Briiggemann, Jennifer A. Smith, Michael J. Osborn,
and Xiangang Zou
5 Bioinformatics Tools for Antibody Engineering 95
Andrew C.R. Martin and James Allen
6 Molecular Engineering I: Humanization 119
Jose W. Saldanha
7 Molecular Engineering II: Antibody Affinity 145
Lorin Roskos, Scott Klakamp, Meina Liang, Rosalin Arends,
and Larry Green
8 Molecular Engineering III: Fc Engineering 171
Matthias Peipp, Thomas Beyer, Michael Dechant, and Thomas Valerius
Part II The Way into the Clinic 197
9 Production and Downstream Processing 199
Klaus Bergemann, Christian Eckermann, Patrick Garidel,
Stefanos Grammatikos, AlexanderJacobi, Hitto Kaufmann,
Ralph Kempken, and Sandra Pisch Heberle
XII I Contents
10 Pharmaceutical Formulation and Clinical Application 239
Cabriele Reich
11 Immunogenicity of Antibody Therapeutics 267
Huub Schellekens, Daan Crommelin, and Wim Jiskoot
12 Regulatory Considerations 277
Marjorie A. Shapiro, Patrick C. Swann, and Melanie Hartsough
13 Intellectual Property Issues 301
Michael Braunagel and Rathin C. Das
Volume III
Overview of Therapeutic Antibodies XXIII
A Greeting by the Editor XXV
Foreword XXVII
List of Authors XXIX
Volume III Approved Therapeutics
1 Adalimumab (Humira) 697
Hartmut Kupper, Jochen Salfeld, Daniel Tracey, and Joachim R. Kalden
2 Alemtuzumab (MabCampath) 733
Thomas Elter, Andreas Engert, and Michael Hallek
3 Bevacizumab (Avastin) 779
Eduardo Diaz Rubio, Edith A. Perez, and Cuiseppe Ciaccone
4 Cetuximab (Erbitux, C 225) 813
Norbert Schleucher and Udo Vanhoefer
5 Efalizumab (Raptiva) 827
Karlheinz Schmitt Rau and Sigbertjahn
6 "Tc Fanolesomab (NeutroSpec) 851
ChristopherJ. Palestro, Josephine N. Rini, and Charito Love
7 Gemtuzumab Ozogamicin (Mylotarg) 869
Matthias Peipp and Martin Cramatzki
Contents I XIII
8 Infliximab (Remicade) 885
Maria Wiekowski and Christian Antoni
9 Muromonab CD3 (Orthoclone OKT3) 905
Harald Becker
10 Natalizumab (Tysabri) 941
Sebastian Schimrigk and RalfCold
11 Omalizumab (Xolair)
Anti lmmunoglobulin E Treatment in Allergic Diseases 951
Claus Kroegel and Martin Foerster
12 Palivizumab (Synagis) 999
Alexander C. Schmidt
13 Rituximab (Rituxan) 1033
Michael Wenger
14 Trastuzumab (Herceptin)
A Treatment for HER2 Positive Breast Cancer 1109
Paul Ellis
15 Abciximab, Arcitumomab, Basiliximab, Capromab, Cotara, Daclizumab,
Edrecolomab, Ibritumomab, Igovomab, Nofetumomab, Satumomab,
Sulesomab, Tositumomab, and Votumumab 1131
Christian Menzel and Stefan Dijbel
Index 1149 |
| any_adam_object | 1 |
| any_adam_object_boolean | 1 |
| author_GND | (DE-588)111685311 |
| building | Verbundindex |
| bvnumber | BV022285710 |
| ctrlnum | (OCoLC)315778616 (DE-599)BVBBV022285710 |
| format | Book |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01076nam a2200277 cc4500</leader><controlfield tag="001">BV022285710</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">00000000000000.0</controlfield><controlfield tag="007">t</controlfield><controlfield tag="008">070226s2007 ad|| |||| 00||| eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)315778616</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV022285710</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-19</subfield><subfield code="a">DE-29</subfield><subfield code="a">DE-355</subfield><subfield code="a">DE-703</subfield><subfield code="a">DE-188</subfield><subfield code="a">DE-578</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">QW 575</subfield><subfield code="2">nlm</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Handbook of therapeutic antibodies</subfield><subfield code="n">2</subfield><subfield code="p">[Emerging developments]</subfield><subfield code="c">ed. by Stefan Dübel</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Weinheim</subfield><subfield code="b">Wiley-VCH</subfield><subfield code="c">2007</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXIX S., S. 325 - 693</subfield><subfield code="b">Ill., graph. Darst.</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">n</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">nc</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Dübel, Stefan</subfield><subfield code="e">Sonstige</subfield><subfield code="0">(DE-588)111685311</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="w">(DE-604)BV022285689</subfield><subfield code="g">2</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">HBZ Datenaustausch</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015495936&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-015495936</subfield></datafield></record></collection> |
| id | DE-604.BV022285710 |
| illustrated | Illustrated |
| index_date | 2024-07-02T16:50:47Z |
| indexdate | 2024-07-09T20:54:09Z |
| institution | BVB |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-015495936 |
| oclc_num | 315778616 |
| open_access_boolean | |
| owner | DE-19 DE-BY-UBM DE-29 DE-355 DE-BY-UBR DE-703 DE-188 DE-578 |
| owner_facet | DE-19 DE-BY-UBM DE-29 DE-355 DE-BY-UBR DE-703 DE-188 DE-578 |
| physical | XXIX S., S. 325 - 693 Ill., graph. Darst. |
| publishDate | 2007 |
| publishDateSearch | 2007 |
| publishDateSort | 2007 |
| publisher | Wiley-VCH |
| record_format | marc |
| spelling | Handbook of therapeutic antibodies 2 [Emerging developments] ed. by Stefan Dübel Weinheim Wiley-VCH 2007 XXIX S., S. 325 - 693 Ill., graph. Darst. txt rdacontent n rdamedia nc rdacarrier Dübel, Stefan Sonstige (DE-588)111685311 oth (DE-604)BV022285689 2 HBZ Datenaustausch application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015495936&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis |
| spellingShingle | Handbook of therapeutic antibodies |
| title | Handbook of therapeutic antibodies |
| title_auth | Handbook of therapeutic antibodies |
| title_exact_search | Handbook of therapeutic antibodies |
| title_exact_search_txtP | Handbook of therapeutic antibodies |
| title_full | Handbook of therapeutic antibodies 2 [Emerging developments] ed. by Stefan Dübel |
| title_fullStr | Handbook of therapeutic antibodies 2 [Emerging developments] ed. by Stefan Dübel |
| title_full_unstemmed | Handbook of therapeutic antibodies 2 [Emerging developments] ed. by Stefan Dübel |
| title_short | Handbook of therapeutic antibodies |
| title_sort | handbook of therapeutic antibodies emerging developments |
| url | http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=015495936&sequence=000002&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA |
| volume_link | (DE-604)BV022285689 |
| work_keys_str_mv | AT dubelstefan handbookoftherapeuticantibodies2 |